nach oben

The European Journal of Health Economics

Erschienen in:

01.12.2005 | Original Papers

Indirect costs of cervical and breast cancers in Spain

verfasst von: Juan Oliva, Félix Lobo, Julio López-Bastida, Néboa Zozaya, Rosa Romay

Erschienen in: The European Journal of Health Economics | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

This study estimated the indirect costs (productivity loss) caused by mortality and morbidity of cervical and breast cancers in Spain. We used two alternative methods: (a) the traditional human capital (HC) approach and (b) the friction cost (FC) method. The annual costs were €43.4 and 288.7 for cervical and breast cancer, respectively, by the HC approach and €1.1 and 11.6 million by the FC approach. Cost-of-illness studies help to illustrate the real dimension of health problems and should be a major concern for health policies. Indirect costs are relevant information about diseases. However, the estimated indirect costs depend heavily on the approach adopted.

American Cancer Society (2001) Cancer facts and figures 2001. American Cancer Society: Atlanta. Available at: http://www.cancer.org (accessed 3 March 2004)

Becker GS (1994) Human capital, 3rd edn. University of Chicago Press: Chicago

Boer R, de Koning HJ, van Oortmarssen GJ, van der Maas PJ (1995) In search of the best upper age limit for breast cancer screening. Eur J Cancer 31A:2040–2043CrossRefPubMed

Boer R, de Koning H, Threlfall A, Warmerdam P, Street A, Friedman E, Woodman C (1998) Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ 317:376–379PubMed

Borghouts JA, Koes BW, Vondeling H, Bouter LM (1999) Cost-of-illness of neck pain in The Netherlands in 1996. Pain 80:629–636CrossRefPubMed

Canadian Coordinating Office for Health Technology Assessment (CCOHTA) (1997) Guidelines for economic evaluation of pharmaceutical, 2nd edn. CCOHTA: Ottawa

Grossman M (1972) The demand for health: a theoretical and empirical investigation. Columbia University Press: New York

Grossman M (2000) The human capital model of the demand for health. In: Culyer AJ, Newhouse JP (eds) Handbook of health economics. North-Holland: Amsterdam

Gyrd-Hansen D, Holund B, Andersen P (1995) A cost-effectivenes analysis of cervical cancer screening: health policy implications. Health Policy 34:35–51CrossRefPubMed

10.

Hodgson TA, Meiners MR (1982) Cost-of-illness methodology: a guide to assessment practices and procedures. Milbank Q 60:429–491

11.

Hutubessy RC, van Tulder MW, Vondeling H, Bouter LM (1999) Indirect costs of back pain in The Netherlands: a comparison of the human capital method with the friction cost method. Pain 80–:201–207

12.

Instituto Nacional de Estadística (INE) (2000). Registro de Defunciones por Causa de Muerte. Available at: http://www.ine.es/inebase/menu2.htm8 (accessed 3 March 2004)

13.

Instituto Nacional de Estadística (INE) (2000) Encuesta de Salarios en la Industria y los Servicios. Available at: http://www.ine.es/inebase/menu2.htm8 (accessed 3 March 2004)

14.

Instituto Nacional de Estadística (INE) (2000) Encuesta de Población Activa. Available at: http://www.ine.es/inebase/menu2.htm8 (accessed 3 March 2004)

15.

Johannesson M, Karlsson G (1997) The friction cost method: a comment. J Health Econ 16:249–255CrossRefPubMed

16.

Johansson PO (1995) Evaluating health risks: an economic approach. Cambridge University Press: Cambridge

17.

Johnson-Thompson MC, Guthrie J (2000) Ongoing research to identify environmental risk factors in breast carcinoma. Cancer 88 [Suppl 5]:1224–1229

18.

Koopmanschap MA, van Ineveld BM (1992) Towards a new approach for estimating indirect costs of disease. Soc Sci Med 34:1005–1010CrossRefPubMed

19.

Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L (1995) The friction cost method for measuring indirect cost of disease. J Health Econ 14:171–189CrossRefPubMed

20.

Leivo T, Sintonen H, Tuominen R, Hakama M, Pukkala E, Heinonen OP (1999) The cost-effectiveness of nationwide breast carcinoma screening in Finland, 1987–1992. Cancer 86:638–646CrossRefPubMed

21.

Liljas B (1998) How to calculate indirect costs in economic evaluation. Pharmacoeconomics 13:1–7PubMed

22.

Lofland JH, Locklear JC, Frick KD (2001) Different approaches to valuing the lost productivity of patients with migraine. Pharmacoeconomics 19:917–925PubMed

23.

López-Abente G et al., unpublished

24.

Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang Y et al. (2002) Benefits and cost of using HPV testing to screen for cervical cancer. JAMA 287:2372–2381CrossRefPubMed

25.

Marcotte DE, Wilcox-Gok V (2001) Estimating the employment and earnings costs of mental illness: recent developments in the United States. Soc Sci Med 53:21–27CrossRefPubMed

26.

Max W, Rice DP, Mackenzie EJ (1990) The lifetime cost of injury. Inquiry 27:332–343PubMed

27.

Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X (2003) The economic burden of gynecologic cancers in California, 1998. Gynecol Oncol 88:96–103CrossRefPubMed

28.

Mettlin C (1999) Global breast cancer mortality statistics. CA Cancer J Clin 49:138–144PubMed

29.

Ministerio de Sanidad y Consumo (2003) Plan integral de la cardiopatía isquémica en España. Available at: http://www.msc.es/Diseno/planesIntegrales/planes_integrales.htm (accessed 3 March 2004)

30.

Mishan EJ (1990) Cost-benefit analysis: an informal introduction, 4th edn. Unwin Hyman: London

31.

Oliva J, Lobo F, López-Bastida J, Duque B, Osuna R (2004) Costes no sanitarios ocasionados por las enfermedades isquémicas del corazón en España. Cuadernos Econ ICE 67:263–298

32.

Olsen JA, Smith RD (2001) Theory versus practice: a review of ‘willingness-to-pay’ in health and health care. Health Econ 10:39–52CrossRefPubMed

33.

Robinson JC (1986) Philosophical origins of the economic valuation of life. Milbank Q 64:133–155PubMed

34.

Thorn TJ (1996) Economic costs of neoplasms, arteriosclerosis, and diabetes in United States. In Vivo 10:255–260PubMed

35.

Tyczynski JE, Bray F, Parkin DM (2002) Breast cancer in Europe. ENCR Cancer Fact Sheets vol 2. Available at: http://www.encr.com.fr/ENCR13.htm (accessed 3 March 2004)

Titel: Indirect costs of cervical and breast cancers in Spain
verfasst von: Juan Oliva
Félix Lobo
Julio López-Bastida
Néboa Zozaya
Rosa Romay
Publikationsdatum: 01.12.2005
Verlag: Springer-Verlag
Erschienen in: The European Journal of Health Economics / Ausgabe 4/2005
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-005-0303-4

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2005

Letter from the Editors

Can economic evaluations be made more transferable?

Estimating utility data from clinical indicators for patients with stable angina

Does testing for prostate-specific antigen contribute to declining prostate cancer mortality?

Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany

Hospital development plans